Australia markets open in 7 hours 54 minutes
  • ALL ORDS

    7,536.10
    -21.70 (-0.29%)
     
  • AUD/USD

    0.7112
    +0.0004 (+0.05%)
     
  • ASX 200

    7,225.20
    -10.70 (-0.15%)
     
  • OIL

    64.85
    -0.72 (-1.10%)
     
  • GOLD

    1,764.10
    -20.20 (-1.13%)
     
  • BTC-AUD

    80,511.39
    -2,476.03 (-2.98%)
     
  • CMC Crypto 200

    1,463.62
    +24.74 (+1.72%)
     

Why Sarepta Therapeutics Fell 14.7% This Week

·2-min read
Why Sarepta Therapeutics Fell 14.7% This Week
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Sarepta Therapeutics (NASDAQ: SRPT), a biotech company that specializes in genetic therapies for rare diseases, dropped 14.7% this week, according to data from S&P Global Market Intelligence. To start the week, the company announced results from its three phase 3 trials for SRP-9001 to treat Duchenne muscular dystrophy (DMD), which is caused by gene mutations that disrupt the dystrophin protein that is crucial for muscle functions. The trials, which measured the response of SRP-9001 on 120 juvenile patients, said that patients improved on the North Star Ambulatory Assessment (NSAA) scale compared with untreated patients.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting